medigraphic.com
Centro Universitario de Ciencias de la Salud de la Universidad de Guadalajara y del OPD Hospitales Civiles de Guadalajara

2005, Number s1

<< Back Next >>

Inv Salud 2005; 7 (s1)

Genetic Predisposition and Chronic Hepatitis C Virus

Vázquez VDM, Román MSM, Vázquez CJL, Panduro CA

Language: Spanish
References: 34
Page: 26-32
PDF size: 237.72 Kb.


ABSTRACT

Chronic hepatitis C virus (HCV) infection is one of the main causes of morbidity and mortality worldwide. The natural course of chronic infection varies importantly between infected individuals. Most infections in adults are self-limited, with clearance of virus. However, some patients will develop chronic hepatitis that can progress to fibrosis and cirrhosis depending on a combination of genetic and environmental factors together with genetic and biological characteristics of HCV. The genetic variability that effects the progression and outcome of the disease depends on factors related to fibrogenesis, grade of hepatic inflammation, and virus binding. The genetic polymorphisms associated to the outcome and severity of the HVC infection are: apolipoprotein E (apoE), genes involved in the immune response, such as, HLA-II, chemokines (RANTES, MCP-1,MCP-2, MIP-1α, CCR2, CCR3, CCR5) and their respective ligands, as well as TNF- α and TGF-β genes.


REFERENCES

  1. World Health Organization. Weekly Epidemiological Record. 1999;74:421-428. Disponible en: www.who.int/wer

  2. Kiyosawa K , Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH. Interrelationship of blood transfusion non-A, non-B hepatitis, and hepatocellular carcinoma. Hepatology, 1990;12:671-675.

  3. Freeman AJ, Kaldor MG, Dore GJ. Predicting progression to cirrhosis in chronic hepatitis c virus infection. J Viral Hepatol, 2003;10(4):285-293.

  4. Poynard T, Bedossa p, Opolon P. Natural history of liver fibrosis progression in patients wiht chronic hepatitis C. Lancet, 1997;349:825-832.

  5. Minuk GY. The influence of host factors on the natural history of chronic hepatitis c viral infections. J Viral Hepatol, 1999;6:271-276.

  6. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology, 2002;36:S47-S56.

  7. Marcus Muhlbauer, Bosserhoff, Hartmann, Thasler, Weiss, Herfarth, Lock, Scholmerich, Hellerbrand. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCVrelated liver disease. Gastroenterology, 2003;125:1085-1093.

  8. Ladero JM. Quimocinas en enfermedades hepáticas: ¿Un nuevo campo de estudio del polimorfismo genético? Rev Española Enf Digest, 2003;95(9):599-602.

  9. Angello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Nat Acad Sci USA, 1999;96:12766-12771.

  10. A. Biología molecular en gastroenterologia y hepatologia. Biología Molecular en la Clinica. McGraw-Hill Interamericana, 2000. Págs. 153-166.

  11. Wozniak MA, Itzhaki RF, Faragher EB, James MW, Ryder SD, Irving WL, Trent HCV study group. Apolipoprotein E-epsilon 4 protects against severe liver disease caused by hepatitis C virus. Hepatology, 2002;36(2):456-63.

  12. Wozniak MA, Itzhaki RF, Faragher EB, James MW, Ryder SD, Irving WL. Apolipoprotein E-e4 protects against severe liver disease caused by hepatitis C virus. Hepatology, 2002;36:456-463.

  13. Itzhaki RF, Irving WL, Wozniak MA. Apolipoprotein E and Hepatitis C virus. Hepatology, 2003;50354:1060.

  14. Carmena R, Ordovas JM. Apolipoproteìna E. Hiperlipidemias. Clìnica y Tratamiento. Doyma. 1999. Págs. 45-63.

  15. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arterioscler Tromb Vasc Biol, 1998;8:1-21.

  16. Escolar JL, Pinzón JL. Infección y lipoproteínas. Enferm Infecc Microbiol Clin, 2000;18:83-86.

  17. Itzhaki R. ApoE involvement in other diseases. Current research. Disponible en: www2.umist.ac.uk

  18. Corpechot C, Benlian P, Barbu V, Chazouilleres O, Poupon RE. Apolipropotein E polymorphism a marker of disease severity in primary biliary cirrosis. J hepatol, 2001;35:324-328.

  19. Mueller T, Gebner R, Sarrazin C, Graf C, Halangk J, Witt H, Köttgen E, Wiedenmann B and Berg T. Apolipoprotein E4 allele is associated with poor treatment response in hepatitis C virus (HCV) genotype 1. Hepatology, 2003 Dec;1592.

  20. Sasaki K, Tsutsumi A, Wakamiya N, Ohtani K, Susuki Y, Watanabe T. Mannose-binding lectin polymorphisms in patients with hepatitis C virus infection. Scand J Gastroenterology, 2000;35:960-965.

  21. Cramp ME, Carucci P, Underhill J, Naouomov NV, Williams R, Donaldson. Association between HLA class II genotype and spontaneous clearance of hepatitis c viremia. J Hepatol, 1998;29(2):207-213.

  22. Alric L, Fort M, Izopet J, Vinel JP, Charlet JP, Selves J, Puel J. Genes of HLA class II influence the outcome of hepatitis C virus infection. Gastroenterology, 1997;113(5):1675-1681.

  23. Minton J, Smillie D, Neal KR, Irving WL, Underwood JCE, James. Association between MHC class II alleles and clearance of circulating hepatitis c virus. J Infect Diseases, 1998;178(1):39-40.

  24. Narumi S, Tominaga Y, Tamaru M, Shimai S, Okumura H, Nishioji K. Expression of IFN-inducible protein-10 in chronic hepatitis. Journal Immunology, 1997;158:5536-5544.

  25. Shimoda K, Begum NA, Shibuta K, Mori M, Bonkovsky HL, Banner BF. Interleukin-8 and hIRH mRNA expression and histologycal activity index in patients with chronic hepatitis C. Hepatology, 1998;28:108-115.

  26. Fernández A, García Monzón. Papel de las quimiocinas en la patogenia de las enfermedades hepáticas. Revista Española de Enfermedades Digestivas, 2003;95(9):607-613.

  27. Hellier, Frodsham, Hnning, Klenerman, Knapp, Ramaley, Satsangi, Wright, Zhang, Thomas, Thursz and Hill. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology, 2003;38(6):1468-1476.

  28. 28 Promrat K, McDermott DH, González CM, Kleiner DE, Koziol DE. Association of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology, 2003;124:352-360.

  29. Jones DE, Watt FE, Grove J, Newton JL, Daly AK, Gregory WL. TNF alfa promoter polymorphism in primary biliary cirrhosis. J Hepatol, 1999;30:232-236.

  30. Tanaka A, Quaranta S, Mattalia A, Coppel R, Rosina and Manns. The TNF-alpha promoter correlates with progression of primary biliary cirrhosis. J Hepatol, 1999;30:826-829.

  31. Yee LJ, Tang J, Herrera J, Kaslow RA, Van Leeuwen DJ. FNT gene polymorphisms in patients with cirrhosis from chronic hepatitis c virus infection. Genes Immun, 2000;1:386-390.

  32. Bedossa P, Paradis V. Transforming growth factor-beta:a key-role in liver fibrogenesis. J Hepatol, 1995;22(suppl):37-42.

  33. Susanne Knapp, Branwen J.W.Henning. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics, 2003;55:362-369.

  34. Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. NEJM, 1991;324:933-940.




2020     |     www.medigraphic.com